3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Available
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
214
Observational
20
Expanded_access
2
Sponsor
Cancer Type
Myeloid
3
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Gynecologic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Lymphoma
13
Recurrence
10
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Non-Hodgkin
7
Leukemia, Myeloid, Acute
7
Leukemia, Lymphocytic, Chronic, B-Cell
6
Lymphoma, Mantle-Cell
5
Leukemia
5
Hodgkin Disease
5
Neoplasms
4
Myelodysplastic Syndromes
4
Multiple Myeloma
4
Waldenstrom Macroglobulinemia
3
Lymphoma, Follicular
3
Hematologic Diseases
3
Sarcoma
2
Primary Myelofibrosis
2
Precancerous Conditions
2
Mastocytosis, Systemic
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma, B-Cell
2
Leukemia, Mast-Cell
2
Immunoproliferative Disorders
2
Immunologic Deficiency Syndromes
2
Immune System Diseases
2
Interventions
venetoclax
1
selinexor
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Expanded_access
×
Primary Myelofibrosis
×
Lymphoid
×
Clear all
NCT07215832
2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT03592576
2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available